Mucosal Immune Responses Against an Oral Enterotoxigenic Escherichia coli Vaccine Evaluated in Clinical Trials.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
20 12 2021
Historique:
pubmed: 23 9 2021
medline: 27 1 2022
entrez: 22 9 2021
Statut: ppublish

Résumé

Enterotoxigenic Escherichia coli (ETEC) is a leading cause of mortality and morbidity in children in low-income countries. We have tested an oral ETEC vaccine, ETVAX, consisting of inactivated E coli overexpressing the most prevalent colonization factors and a toxoid, LCTBA, administered together with a mucosal adjuvant, double-mutant heat-labile toxin (dmLT), for capacity to induce mucosal immune responses and immunological memory against the primary vaccine antigens, ie, colonization factors, heat-labile toxin B-subunit and O antigen. The studies show that ETVAX could induce strong intestine-derived and/or fecal immune responses in a majority of vaccinated Swedish adults and in different age groups, including infants, in Bangladesh.

Identifiants

pubmed: 34550392
pii: 6373960
doi: 10.1093/infdis/jiab475
pmc: PMC8687049
doi:

Substances chimiques

Antibodies, Bacterial 0
Enterotoxins 0
Escherichia coli Proteins 0
Escherichia coli Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

S821-S828

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

Clin Microbiol Rev. 2005 Jul;18(3):465-83
pubmed: 16020685
Vaccine. 2013 May 7;31(20):2457-64
pubmed: 23541621
Vaccine. 2019 Sep 3;37(37):5645-5656
pubmed: 30473185
Vaccine. 2014 Dec 12;32(52):7077-84
pubmed: 25444830
Trends Microbiol. 1996 Nov;4(11):444-52
pubmed: 8950814
Vaccine. 2013 Feb 6;31(8):1163-70
pubmed: 23306362
Lancet Infect Dis. 2020 Feb;20(2):208-219
pubmed: 31757774
Heliyon. 2018 Feb 01;4(1):e00519
pubmed: 29560435
Vaccine. 2016 Jun 8;34(27):3132-3140
pubmed: 27133878
mSphere. 2018 Jul 25;3(4):
pubmed: 30045966
Vaccine. 2013 Jun 26;31(30):3035-8
pubmed: 23664997
Expert Rev Vaccines. 2012 Apr;11(4):495-507
pubmed: 22551034
Infect Immun. 2007 Aug;75(8):3961-8
pubmed: 17548483
Vaccine. 2017 Jul 13;35(32):3966-3973
pubmed: 28625524
Infect Immun. 2004 Dec;72(12):7190-201
pubmed: 15557644
Vaccine. 2007 May 30;25(22):4392-400
pubmed: 17448578

Auteurs

Ann-Mari Svennerholm (AM)

Department of Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden.

Anna Lundgren (A)

Department of Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden.

Susannah Leach (S)

Department of Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden.
Department of Clinical Pharmacology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Marjahan Akhtar (M)

Infectious Diseases Division of icddr,b, Dhaka, Bangladesh.

Firdausi Qadri (F)

Infectious Diseases Division of icddr,b, Dhaka, Bangladesh.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH